JENAVALVE APPOINTS VICTORIA E. CARR-BRENDEL, PH.D., AS CHIEF EXECUTIVE OFFICER

Munich, Germany and Irvine, California – June 1, 2015 – JenaValve Technology, Inc., a developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of seasoned medical device executive Victoria E. Carr-Brendel, Ph.D., as chief executive officer, effective immediately.

Dr. Carr-Brendel replaces Jan Keltjens, who served as interim CEO since January 2015. Mr. Keltjens will remain chairman of the JenaValve board and will support Dr. Carr-Brendel during a transition period.

Dr. Carr-Brendel joins JenaValve from Boston Scientific Corporation and brings to JenaValve more than 25 years of medical device leadership experience, including the development and commercialization of numerous advanced medical devices across disease states. She has a breadth of innovation, regulatory, clinical and strategic business experience in the medical device sector. Dr. Carr-Brendel will be based in Irvine, Calif. at JenaValve's new corporate headquarters.

"With an impressive background and proven leadership in the medical device sector, Dr. Carr-Brendel is ideally qualified to lead JenaValve through its next phase of growth and position JenaValve as an important player in the large and rapidly growing worldwide TAVR market," said Mr. Keltjens. "Our global team has worked diligently over the past several months to complete the design of our new pericardial tissue valve and transfemoral delivery system, and we will continue clinical work soon to support regulatory approval."

Prior to joining JenaValve, Dr. Carr-Brendel served as general manager of Boston Scientific's Bayer Interventional business. In this role she executed a successful commercial growth and integration strategy. Managing a business unit of 350 employees, Dr. Carr-Brendel was responsible for product development programs, setting commercial development strategy and overseeing program execution. Previously, she held various roles at Boston Scientific, including franchise general manager of the Peripheral Interventions division, vice president of research and development of the electrophysiology division, and director of research and development of the neurovascular division.

"Given JenaValve's unique pericardial tissue valve and new transapical and transfemoral delivery systems, the company is poised to become a leader in transcatheter aortic valve repair," said Dr. Carr-Brendel. "JenaValve is an innovative, nimble company that holds promise to make a significant impact in this competitive, growing market. I am confident that my product development expertise and experience in the commercialization of complex cardiovascular products are a perfect fit as we launch our new TAVR system worldwide. It is my intention to lead JenaValve to achieve the promise that the investors and employees have worked at over the past years for patients in need."

"Our enhanced organizational focus, with corporate headquarters and innovation driven from Irvine, Calif. and global commercialization led from our Munich, Germany office, makes us well positioned for the European launch of our next-generation TAVR platform," said Mr. Keltjens. "Given the large and rapidly growing market opportunity, our global team of talented, motivated employees and unwavering support from our investors, and now the added leadership of Dr. Carr-Brendel, we are truly excited about our future and fully expect to be competitive in this marketplace."

About JenaValve
JenaValve Technology, with operating locations in Munich, Germany and Irvine, California, develops, manufactures and markets transcatheter aortic valve repair (TAVR) systems to treat patients suffering from aortic valve disease. The Company's Transapical TAVR system, consisting of the JenaValve valve system plus Cathlete PLUS delivery system, has CE Mark approval for aortic valve stenosis and for the unique indication to treat patients suffering from aortic valve insufficiency. JenaValve currently markets this product in Europe and other selected markets worldwide. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, Legend Capital, NeoMed Management, Omega Funds, RMM, Sunstone Capital, Valiance Advisors and VI Partners.

Additional information is available at www.jenavalve.com.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.